A Comparison of Three Extrusion Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Comparison of Three Extrusion Systems
The authors conducted an experiment to determine the type of extrusion that provides the best productivity and pellet quality. This article contains online bonus material.


Pharmaceutical Technology
Volume 35, Issue 1

16. D. Sonaglio et al., Pharmazie 52 (2), 129–134 (1997).

17. D. Djuric et al., Eur. J. Pharm. Biopharm. 71 (1), 155–160 (2009).

18. A. Debunne, C. Vervaet, and J.P. Remon, Eur. J. Pharm. Biopharm. 54 (3), 343–348 (2002).

19. A. Dukić et al., Eur. J. Pharm. Biopharm. 66 (1), 83–94 (2007).

20. H. Kanbe et al., Int. J. Pharm. 337 (1–2), 56–62 (2007).

21. A. Dukić-Ott et al., Eur. J. Pharm. Biopharm. 70 (1), 302–312 (2008).

22. K.E. Fielden, J.M. Newton, and R.C. Rowe, Int. J. Pharm. 97 (1–3), 79–92 (1993).

23. E. Jerwanska et al., Int. J. Pharm. 121 (1), 65–71 (1995).

24. J.J. Sousa et al., Int. J. Pharm. 144 (2), 159–169 (1996).

25. L. Hellén et al., J. Pharm. Tech. Int. 4 (9), 50–60 (1992).

26. G.A. Hileman et al., Int. J. Pharm. 100 (1–3), 71–79 (1993).

27. C.C. Ku et al., Drug Dev. Ind. Pharm. 19 (13), 1505–1519 (1993).

28. B. Bataille, K. Ligarski, and M. Jacob, Pharm. Acta Helv. 65 (12), 334–337 (1990).

29. D. Sonaglio et al., Int. J. Pharm. 115 (1), 53–60 (1995).

30. K.A. Mehta et al., J. Control. Release 63 (1–2), 201–211 (2000).

31. S. Galland et al., Chem. Eng. Res. Des. 81 (9), 1237–1242 (2003).

32. S. Galland et al., Powder Technol. 157 (1–3), 156–162 (2005).

33. P. Kleinebudde and H. Lindner, Int. J. Pharm. 94 (1–3), 49–58 (1993).

34. D. Lutchman, C.M. Dangor, and D. Perumal, J. Microencapsul. 22 (6), 643–659 (2005).

35. C. Vervaet et al., Int. J. Pharm. 107 (1), 29–39 (1994).

36. C. Vervaet and J.P. Remon, Int. J. Pharm. 133 (1–2), 29–37 (1996).

37. R. Dietrich and R. Brausse, Pharm. Ind. 50 (10), 1179–1186 (1988).

38. A.M. Juppo et al., Eur. J. Pharm. Biopharm. 44 (2) 205–214 (1997).

39. P.J. Harrison, J.M. Newton, and R.C. Rowe, J. Pharm. Pharmacol. 37 (10), 686–691 (1985).

40. J.F. Pinto, G. Buckton, and J.M. Newton, Int. J. Pharm. 83 (1–3), 187–196 (1992).

41. L. Baert and G.R.B. Down, Int. J. Pharm. 107 (3), 219–222 (1994).

42. C. Lustig-Gustafsson et al., Eur. J. Pharm. Sci. 8 (2), 147–152 (1999).

43. G. Tomer, F.Podczeck, and J.M. Newton, Int. J. Pharm. 217 (1–2), 237–248 (2001).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here